二肽基肽酶-4抑制剂西格列汀联合二甲双胍治疗2型糖尿病的疗效被引量：16

导出

摘要目的探讨二肽基肽酶-4抑制剂西格列汀联合二甲双胍治疗新诊断2型糖尿病(T2DM)的疗效及安全性。方法选取新诊断T2DM患者60例,随机分为观察组及对照组,每组30例。两组患者均进行糖尿病教育,均口服二甲双胍每次0.5g,每天3次。观察组在此基础上加用西格列汀口服,每次100mg,每天1次。治疗24周后比较两组降糖的效果及安全性。结果治疗24周后,两组FBG、餐后2h血糖及HbA1c水平均较治疗前下降(P<0.05),观察组患者上述指标低于对照组(P<0.05);治疗后两组空腹胰岛素(FIns)、胰岛素分泌指数(HOMA-β)升高,HOMA-IR下降(P<0.05);观察组FIns、HOMA-β均高于对照组(P<0.05)。观察组HbA1c达标率高于对照组(85.1%vs.68.2%)(P<0.05)。治疗过程中,两组各有1例发生低血糖反应;观察组发生消化道不良反应6例,对照组5例。结论对新诊断T2DM患者进行西格列汀联合二甲双胍治疗可有效控制血糖,有效改善胰岛β细胞功能。

作者戚蓓蓓宋文春江冬梅纪敏

机构地区盐城市第三人民医院内分泌病科

出处《江苏医药》 CAS 2016年第15期1728-1729,共2页 Jiangsu Medical Journal

关键词西格列汀二甲双胍 2型糖尿病

分类号 R587 [医药卫生—内分泌]

引文网络
相关文献

参考文献7

1Ahren B,Pacini G,Foley JE,et al.Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over I years[J].Diabetes Care,2005,28(8):1936-1940.
2Iwasaki M,Hoshian F,Tsuji T,et al. Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes:association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels[J].J Diabetes Investig,2012,3(5):464-467.
3邵蔚,杜宁迁.甘精胰岛素联合二甲双胍或／和阿卡波糖治疗新诊断2型糖尿病疗效观察[J].中国实用医刊,2014,41(3):14-16. 被引量：9
4Krentz AJ,Bailey CJ.Oral antidiabetic agents:current role in type 2 diabetes mellitus[J].Drugs,2005,65(3):385-411.
5Setter SM,Iltz JL,Thams J,et al.Metformin hydrochloride in the treatment of type 2 diabetes mellitus:a clinical review with a focus on dual therapy[J].Clin Ther,2003,25(12):2991-3026.
6Hundal RS,Inzucchi SE.Metformin:new understandings,new uses[J].Drugs,2003,63(18):1879-1894.
7韩峰,刘晓丽,姜彩霞,杨丽娜,邢翠红,任建民.沙格列汀对初诊2型糖尿病患者血糖、胰岛功能的影响[J].山东医药,2014,54(13):47-48. 被引量：7

二级参考文献19

1郦文琴,殷洪二,薛庆培.胰岛素联合二甲双胍短期强化治疗对2型糖尿病胰岛β细胞功能的影响[J].临床荟萃,2006,21(5):325-327. 被引量：18
2衡先培,杨柳清,翁苓,谢瑜,李秀钧.二甲双胍的临床应用[J].国际内分泌代谢杂志,2006,26(3):152-154. 被引量：13
3Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD (P)H- oxidase activation[ J]. Diabetes, 2003,52( 11 ) :2795-804.
4雷闽湘.糖尿病[M]//廖二元,超楚声.内分泌学.2版.北京:人民卫生出版社,2003:1434-1496.
5Coke B. Islet cell function:alpha and beta cells-partners towards normoelycaemia [ J ]. Int J Clio Pract Suppl, 2008,159:2-7.
6Salehi M, Aulinger BA, Dlessio DA. Targeting B cell mass in type 2 diabetes : promise and limetations of new drugs based on incretins [J]. Endocr Rev, 2008,29(3) :367-379.
7Marl A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl pep- tidase-IV inhibitor, improves model assessed beta cell function in patients with type 2 diabetes[J]. J Clin Endoerinol Melab, 2005, 90 ( 8 ) :4888-4894.
8Maria A, Scherbaum WA, Nilsson PM. et al. Characterization of the influence of vildagliptin on model assessed cell function in pa- tients with type 2 diabetes and mild hyperelyeemia[ J]. J Clin En- docrinol Metab, 2008,93 ( 1 ) : 103-109.
9Tsuboi T, da Sila Xaver G, Holz GG, et al. Glucagon-like pep- tided mobilizes intracellular Ca^2+ and stimmulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cell [ J ]. Biochem J, 2003,369( Pt 2) :287-299.
10Kang G, Chepurny OG, Rinder MJ, et al. A cAMP and Ca^2 + coin- cidence detector in support of Ca^2 + -induced Ca^2 + release in mouse pancreatic beta cells[ J ]. J Physiol, 21305,566( Pt 1 ) : 173-188.